



WEST Search History

DATE: Thursday, February 02, 2006

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L6	((514/9 and lyoph\$ and L4))!	111
<input type="checkbox"/>	L5	lyoph\$ and L4	7609
<input type="checkbox"/>	L4	(peptide or protein or polypeptide or amino adj acid) and L3	16992
<input type="checkbox"/>	L3	cyclic and L2	19842
<input type="checkbox"/>	L2	fung\$ and (lactose or maltose or sucrose or disaccharide or polysaccharide or sodium adj chloride)	65383
		<i>DB=USPT; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L1	6774104.pn.	1

END OF SEARCH HISTORY



chain nodes :

1 19 20 21 22 23 24

ring nodes :

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-4 1-23 1-24 7-8 10-14 17-19 19-20 20-21 21-22

ring bonds :

2-3 2-7 3-4 4-5 5-6 6-7 8-9 8-11 9-10 10-12 11-12 13-14 13-18 14-15 15-16
16-17 17-18

exact/norm bonds :

1-23 1-24 8-9 8-11 9-10 10-12 11-12 17-19 19-20

exact bonds :



1-4 7-8 10-14 20-21 21-22

normalized bonds :

2-3 2-7 3-4 4-5 5-6 6-7 13-14 13-18 14-15 15-16 16-17 17-18

Match level :

1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS



chain nodes :

1 19 20 21 22 23 24 25 26 27 28 29 30 31 32

ring nodes :

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-4 1-30 1-31 7-8 10-14 17-19 19-20 20-21 20-23 20-24 21-22 21-25 21-26
22-29 22-27 22-28 31-32

ring bonds :

2-3 2-7 3-4 4-5 5-6 6-7 8-9 8-11 9-10 10-12 11-12 13-14 13-18 14-15 15-16
16-17 17-18

exact/norm bonds :

1-30 1-31 8-9 8-11 9-10 10-12 11-12 17-19 19-20

exact bonds :

1-4 7-8 10-14 20-21 20-23 20-24 21-22 21-25 21-26 22-29 22-27 22-28 31-32

normalized bonds :

2-3 2-7 3-4 4-5 5-6 6-7 13-14 13-18 14-15 15-16 16-17 17-18


Match level :

1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS


L7 73 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Deoxymulundocandin, 1-[(4R)-4-[[[(1R,2R)-2-aminocyclohexyl]amino]-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine] - (9CI)
 SQL 6
 MF C60 H80 N10 O15
 CI COM


RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-A



PAGE 2-A






L7 73 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Pneumocandin A0, 1-[(4R)-4-hydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine] - (9CI)
 SQL 6
 MF C56 H71 N9 O21 S
 CI COM


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 73 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Echinocandin B, 1-[(4R)-4-hydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[4-[4-hydroxy-3-(sulfooxy)phenyl]-L-

threonine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI)
SQL 6
MF C56 H73 N9 O20 S


RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 73 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Echinocandin B, 1-[(4R)-N2-[4-[5-[4-[[7-[(2R,6S)-2,6-dimethyl-4-morpholinyl]heptyl]oxy]phenyl]-3-isoxazolyl]benzoyl]-4-hydroxy-L-ornithine]-4-[4-[4-[(2-propenyloxy)carbonyl]oxy]-3-(sulfooxy)phenyl]-L-threonine]-5-[(3R)-3-hydroxy-N5-[2-hydroxy-1-(hydroxymethyl)ethyl]-N5-[(2-propenyloxy)carbonyl]-L-ornithine]- (9CI)
MF C75 H102 N10 O27 S
CI COM


Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





(FILE 'HOME' ENTERED AT 23:07:18 ON 02 FEB 2006)

FILE 'REGISTRY' ENTERED AT 23:07:27 ON 02 FEB 2006

L1	STRUCTURE UPLOADED
L2	0 S L1 FAM SAM
L3	0 S L1 FAM FULL
L4	STRUCTURE UPLOADED
L5	0 S L4 FAM SAM
L6	3 S L4 SSS SAM
L7	73 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 23:19:29 ON 02 FEB 2006

L8	157 S L7
L9	157446 S L8 AND LACTOSE OR SUCROSE OR MALTOSE
L10	4 S L8 AND (LACTOSE OR SUCROSE OR MALTOSE)
L11	140 S L8 AND (FUNGAL OR FUNGUS OR FUNG?)
L12	0 S L11 AND LYOPH?
L13	2 S L11 AND (POLYSACCHARID? OR DISACCHARID? OR SODIUM CHLORIDE)

(FILE 'HOME' ENTERED AT 23:07:18 ON 02 FEB 2006)

FILE 'REGISTRY' ENTERED AT 23:07:27 ON 02 FEB 2006

L1 STRUCTURE UPLOADED
L2 0 S L1 FAM SAM
L3 0 S L1 FAM FULL
L4 STRUCTURE UPLOADED
L5 0 S L4 FAM SAM
L6 3 S L4 SSS SAM
L7 73 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 23:19:29 ON 02 FEB 2006

=> s 17

L8 157 L7

=> s 18 and lactose or sucrose or maltose

49217 LACTOSE
93 LACTOSES
49225 LACTOSE
(LACTOSE OR LACTOSES)
139861 SUCROSE
92 SUCROSES
139872 SUCROSE
(SUCROSE OR SUCROSES)
26661 MALTOSE
40 MALTOSES
26667 MALTOSE
(MALTOSE OR MALTOSES)

L9 157446 L8 AND LACTOSE OR SUCROSE OR MALTOSE

=> s 18 and (lactose or sucrose or maltose)

49217 LACTOSE
93 LACTOSES
49225 LACTOSE
(LACTOSE OR LACTOSES)
139861 SUCROSE
92 SUCROSES
139872 SUCROSE
(SUCROSE OR SUCROSES)
26661 MALTOSE
40 MALTOSES
26667 MALTOSE
(MALTOSE OR MALTOSES)

L10 4 L8 AND (LACTOSE OR SUCROSE OR MALTOSE)

=> d l10 1-4 bib abs

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:612064 CAPLUS

DN 143:139157

TI Preparation of rigid liposomal cochleate

IN Krause-Elsmore, Sara L.; Mannino, Raphael J.

PA Biodelivery Sciences International, Inc., USA

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063213	A1	20050714	WO 2004-US42927	20041220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

PRAI US 2003-531546P P 20031219
US 2004-565120P P 20040423

AB Employing liposomes having a high transition temperature at least partially disposed in a matrix, compns. are provided that can be used to deliver one or more cargo moieties, e.g., a drug, a nutrient, an imaging agent and/or nonsteroidal anti-inflammatory drug. The matrix can be a lipid precipitate and/or a cationic bridge. Methods of making and using these compns. preferably cochleates, are also disclosed. Rigid liposomes were obtained from distearoylphosphatidylserine and dextran.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:902155 CAPLUS

DN 141:384286

TI Novel encochleation methods, cochleates and methods of use

IN Mannino, Raphael J.; Gould-Fogerite, Susan; Krause-Elsmore, Sara L.;
Delmarre, David; Lu, Ruying

PA Biodelivery Sciences International, Inc., USA; University of Medicine and
Dentistry of New Jersey

SO PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091578	A2	20041028	WO 2004-US11026	20040409
	WO 2004091578	C1	20050127		
	WO 2004091578	A3	20050331		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

	US 2005013854	A1	20050120	US 2004-822230	20040409
PRAI	US 2003-461483P	P	20030409		
	US 2003-463076P	P	20030415		
	US 2003-499247P	P	20030828		
	US 2003-502557P	P	20030911		
	US 2003-532755P	P	20031224		
	US 2004-537252P	P	20040115		
	US 2004-556192P	P	20040324		

AB The invention generally relates to cochleate drug delivery vehicles. Disclose are novel methods for making cochleates and cochleate compns. that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compns. that include an aggregation inhibitor, and optionally, a cargo moiety. Addnl., anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a neg. charge lipid are disclosed. Methods of using the cochleate compns. of the invention, including methods of administration, are also disclosed.

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:757023 CAPLUS

DN 139:281230

TI Bioadhesive vaginal drug delivery system containing an acidic buffer
 IN Kirschner, Mitchell I.; Levinson, R. Saul; Riley, Thomas C.; Hermelin, Marc S.
 PA KV Pharmaceutical Company, USA
 SO U.S. Pat. Appl. Publ., 13 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003180366	A1	20030925	US 2002-101014	20020320
	US 6899890	B2	20050531		
	CA 2392473	AA	20030920	CA 2002-2392473	20020628
	BR 2002002767	A	20040525	BR 2002-2767	20020718
	CN 1444926	A	20031001	CN 2002-127087	20020729
	JP 2003286193	A2	20031007	JP 2002-266381	20020912
	PT 102854	A	20030930	PT 2002-102854	20021015
	PT 102854	B	20040227		
	FR 2837389	A1	20030926	FR 2002-14858	20021127
	WO 2003079981	A2	20031002	WO 2003-US8266	20030319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2002-101014 A 20020320

AB The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insol. phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase. For example, a vaginal drug delivery system was prepared containing metronidazole 0.75%, water 24.676%, glycerin 47.25%, acetic acid 0.225%, sodium acetate 0.20%, sodium chloride 0.75%, methylparaben 0.09%, propylparaben 0.035%, butylparaben 0.024%, **sucrose** 8.0%, mineral oil 13.0%, and polyethylene glycol (30) dipolyhydroxystearate 5.0%.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:31345 CAPLUS

DN 134:105851

TI Stabilized cyclic polypeptide pharmaceutical composition in lyophilized form

IN Sawai, Seiji; Kasai, Akihiro; Otomo, Kazumi

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002002	A1	20010111	WO 2000-JP4381	20000629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,				

ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2341568	AA	20010111	CA 2000-2341568	20000629
AU 2000055722	A5	20010122	AU 2000-55722	20000629
AU 752265	B2	20020912		
BR 2000006823	A	20010605	BR 2000-6823	20000629
EP 1107777	A1	20010620	EP 2000-940916	20000629
EP 1107777	B1	20041027		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE,
SI, LT, LV, FI, RO

TR 200100609	T1	20010723	TR 2001-200100609	20000629
JP 2002363097	A2	20021218	JP 2001-312701	20000629
JP 2003503462	T2	20030128	JP 2001-507492	20000629
JP 3381722	B2	20030304		
NZ 510290	A	20030725	NZ 2000-510290	20000629
AT 280583	E	20041115	AT 2000-940916	20000629
PT 1107777	T	20050131	PT 2000-940916	20000629
ES 2225161	T3	20050316	ES 2000-940916	20000629
RU 2251411	C2	20050510	RU 2001-108569	20000629
CZ 295720	B6	20051012	CZ 2001-1186	20000629
NO 2001000893	A	20010424	NO 2001-893	20010222
ZA 2001001589	A	20020902	ZA 2001-1589	20010226
US 6774104	B1	20040810	US 2001-786125	20010301
HK 1040057	A1	20050805	HK 2002-101689	20020305
US 2004157769	A1	20040812	US 2004-772281	20040206

PRAI JP 1999-187713 A 19990701
JP 2001-507492 A3 20000629
WO 2000-JP4381 W 20000629
US 2001-786125 A3 20010301

OS MARPAT 134:105851

AB A stabilized pharmaceutical composition in lyophilized form comprises a cyclic polypeptide and one or more stabilizer(s) selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride. A composition was prepared containing a cyclic polypeptide and **lactose**.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT